Drugs / Chlorphenesin Carbamate
Chlorphenesin Carbamate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MAOLATE | — | 1965-06-14 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05083780 | Nov 2021 → Dec 2025 overdue | malignant pancreatic neoplasm | Changhoon Yoo | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chlorphenesin Carbamate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05083780 ↗ |
| Known as | Chlorphenesine | ChEMBL registry synonym — accepted as the source's own label CHEMBL607710 ↗ |
| Known as | Clorfenesina | ChEMBL registry synonym — accepted as the source's own label CHEMBL607710 ↗ |
| Known as | Maolate | ChEMBL registry synonym — accepted as the source's own label CHEMBL607710 ↗ |
| Known as | NSC-82943 | ChEMBL registry synonym — accepted as the source's own label CHEMBL607710 ↗ |
| Known as | U-19,646 | ChEMBL registry synonym — accepted as the source's own label CHEMBL607710 ↗ |
| Modality | Small molecule | — CHEMBL607710 ↗ |
| Route | Oral | “chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily” NCT05083780 ↗ |